Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503060 | 0.87 | NAPRT (0.52) | KDM4EKMT2ANAPRTTP53MPO | |
| SCHEMBL2988329 | 0.83 | NAPRT (0.48) | KDM4EKMT2ANAPRTTP53MPO | |
| SCHEMBL7554003 | 0.83 | KMT2A (0.45) | KDM4EKMT2ANAPRTMPOCYP1A2 | |
| SCHEMBL7554228 | 0.80 | KMT2A (0.42) | KDM4EKMT2ANAPRTTP53MPO | |
| SCHEMBL3935110 | 0.80 | NAPRT (0.45) | KDM4EKMT2ANAPRTMPOCYP1A2 | |
| SCHEMBL6614684 | 0.80 | NAPRT (0.45) | KDM4EKMT2ANAPRTMPOCYP1A2 | |
| SCHEMBL21805934 | 0.79 | KDM4E (0.45) | KDM4EKMT2ANAPRTTP53MPO | |
| SCHEMBL7584545 | 0.79 | KDM4E (0.44) | KDM4EKMT2ANAPRTMPOCYP1A2 | |
| SCHEMBL11590778 | 0.79 | KDM4E (0.56) | KDM4EKMT2ANAPRTTP53MPO | |
| SCHEMBL5452316 | 0.79 | CES2 (0.46) | NAPRTCYP3A4CYP2C19LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101678-A1 | METHOD FOR SCREENING RISK OF DRUG-INDUCED TOXICITY | RESEARCH CENTER FOR BIOTECHNOLOGY AND MEDICINE POLICY (TW) | 2017-04-13 | — | — | US | disclosed |
| CN-105940116-A | Method for screening risk of drug-induced toxicity | 财团法人生技医疗科技政策研究中心 | 2016-09-14 | — | — | CN | disclosed |
| WO-2015109608-A1 | METHOD FOR SCREENING RISK OF DRUG-INDUCED TOXICITY | 财团法人生技医疗科技政策研究中心 | 2015-07-30 | — | — | WO | disclosed |
| US-8577617-B2 | Metabolic phenotyping | CLAYTON THOMAS ANDREW (GB) | 2013-11-05 | — | — | US | disclosed |
| EP-1540560-B1 | METABOLIC PHENOTYPING | PFIZER LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| WO-2010037134-A2 | MULTI-STAGE STEM CELL CARCINOGENESIS | STEMLIFELINE, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20090192721-A1 | METABOLIC PHENOTYPING | PFIZER INC | 2009-07-30 | — | — | US | disclosed |
| EP-1540560-A2 | METABOLIC PHENOTYPING | Pfizer Limited (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20050074745-A1 | Metabolic phenotyping | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| WO-2003107270-A2 | METABOLIC PHENOTYPING | PFIZER LIMITED (GB) | 2003-12-24 | — | — | WO | disclosed |
| WO-2002043668-A2 | ANTIMYCOBACTERIAL COMPOUNDS AND METHOD FOR MAKING THE SAME | WELLESLEY COLLEGE (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | KDM4E 3169/4885KMT2A 4030/4885NAPRT 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.